A detailed history of Assenagon Asset Management S.A. transactions in Regenxbio Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 559,872 shares of RGNX stock, worth $4.27 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
559,872
Previous 816,384 31.42%
Holding current value
$4.27 Million
Previous $9.55 Million 38.51%
% of portfolio
0.01%
Previous 0.02%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$10.49 - $14.39 $2.69 Million - $3.69 Million
-256,512 Reduced 31.42%
559,872 $5.87 Million
Q2 2024

Jul 18, 2024

BUY
$11.51 - $21.53 $6.78 Million - $12.7 Million
588,773 Added 258.68%
816,384 $9.55 Million
Q1 2024

Apr 24, 2024

BUY
$12.17 - $24.61 $1.47 Million - $2.98 Million
120,929 Added 113.35%
227,611 $4.8 Million
Q4 2023

Jan 17, 2024

BUY
$12.89 - $20.82 $1.38 Million - $2.22 Million
106,682 New
106,682 $1.91 Million
Q1 2022

Apr 25, 2022

BUY
$24.62 - $34.31 $2.1 Million - $2.93 Million
85,438 Added 30.77%
363,138 $12.1 Million
Q4 2021

Feb 01, 2022

BUY
$30.19 - $40.28 $4.22 Million - $5.64 Million
139,947 Added 101.59%
277,700 $9.08 Million
Q3 2021

Oct 19, 2021

BUY
$29.09 - $45.68 $4.01 Million - $6.29 Million
137,753 New
137,753 $5.78 Million
Q3 2020

Oct 07, 2020

SELL
$27.01 - $40.26 $1.25 Million - $1.86 Million
-46,292 Closed
0 $0
Q2 2020

Jul 21, 2020

SELL
$27.75 - $43.44 $588,300 - $920,928
-21,200 Reduced 31.41%
46,292 $1.71 Million
Q1 2020

Apr 17, 2020

BUY
$21.5 - $54.2 $1.45 Million - $3.66 Million
67,492 New
67,492 $2.19 Million

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $329M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.